News

Date	Title and Summary	Additional Formats
Toggle SummaryApr 03, 2013	Intersect ENT Vice President Susan Stimson Honored As “Marketer That Matters”	Intersect ENT Vice President Susan Stimson Honored As “Marketer That Matters” 31.8 KB
Toggle SummaryMay 03, 2013	Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area’s “Most Influential Women in Business”	Intersect ENT President and CEO Lisa Earnhardt Named One of Bay Area’s “Most Influential Women in Business” 32.1 KB
Toggle SummarySep 30, 2013	Intersect ENT Announces Positive Results from Pilot Study of Novel In-Office Implant for Chronic Sinusitis Patients	Intersect ENT Announces Positive Results from Pilot Study of Novel In-Office Implant for Chronic Sinusitis Patients 29.9 KB
Toggle SummaryOct 15, 2013	Intersect ENT Named One of the “Fierce 15” Most Promising Private Companies by FierceMedicalDevices	Intersect ENT Named One of the “Fierce 15” Most Promising Private Companies by FierceMedicalDevices 176.8 KB
Toggle SummaryJan 08, 2014	Intersect ENT to Present at the 32nd Annual J.P. Morgan Healthcare Conference	Intersect ENT to Present at the 32nd Annual J.P. Morgan Healthcare Conference 119 KB
Toggle SummaryJan 23, 2014	Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies” of 2014	Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies” of 2014 24.7 KB
Toggle SummaryJun 01, 2014	Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman	Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman 81.2 KB
Toggle SummaryJul 11, 2014	Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors	Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors 24.5 KB
Toggle SummaryJul 24, 2014	Intersect ENT Announces Pricing of Its Initial Public Offering MENLO PARK, Calif., July 24, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc., a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the pricing of its initial public offering of 5,000,000 shares of its common	View HTML Intersect ENT Announces Pricing of Its Initial Public Offering 11.1 KB
Toggle SummaryJul 29, 2014	Intersect ENT Announces Closing of its Initial Public Offering MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of	View HTML Intersect ENT Announces Closing of its Initial Public Offering 10.2 KB

Investor Relations

News